ArQule (ARQL) Price Target Increased to $7.00 by Analysts at Needham & Company LLC

Share on StockTwits

ArQule (NASDAQ:ARQL) had its price objective raised by Needham & Company LLC from $6.00 to $7.00 in a report published on Monday. They currently have a buy rating on the biotechnology company’s stock.

ARQL has been the subject of several other reports. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $3.25 price target for the company in a report on Friday, April 6th. BidaskClub downgraded ArQule from a strong-buy rating to a buy rating in a research note on Saturday, April 7th. Roth Capital initiated coverage on ArQule in a research note on Thursday, February 22nd. They issued a buy rating and a $5.00 price objective on the stock. ValuEngine downgraded ArQule from a strong-buy rating to a buy rating in a research note on Friday, June 1st. Finally, Oppenheimer initiated coverage on ArQule in a research note on Tuesday, June 12th. They issued an outperform rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $5.35.

Shares of ArQule opened at $5.00 on Monday, MarketBeat reports. The company has a current ratio of 5.42, a quick ratio of 5.42 and a debt-to-equity ratio of 1.50. ArQule has a 52-week low of $0.94 and a 52-week high of $6.07.

ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01). The firm had revenue of $4.14 million during the quarter, compared to analyst estimates of $2.27 million. During the same period last year, the company posted ($0.11) EPS. sell-side analysts forecast that ArQule will post -0.24 EPS for the current year.

In other ArQule news, insider Value Fund L. P. Biotechnology sold 2,301,581 shares of ArQule stock in a transaction that occurred on Wednesday, April 4th. The stock was sold at an average price of $2.90, for a total value of $6,674,584.90. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Paolo Pucci purchased 15,000 shares of the company’s stock in a transaction on Friday, May 18th. The stock was acquired at an average cost of $3.39 per share, for a total transaction of $50,850.00. Following the completion of the transaction, the chief executive officer now owns 420,494 shares in the company, valued at $1,425,474.66. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 57,257 shares of company stock worth $171,425 and sold 5,567,893 shares worth $18,768,436. 7.90% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC increased its position in ArQule by 1,631.7% in the 1st quarter. Millennium Management LLC now owns 1,726,984 shares of the biotechnology company’s stock worth $4,974,000 after buying an additional 1,627,259 shares during the period. Jane Street Group LLC bought a new position in ArQule in the 1st quarter worth approximately $100,000. Element Capital Management LLC bought a new position in ArQule in the 1st quarter worth approximately $225,000. Arnhold LLC bought a new position in ArQule in the 1st quarter worth approximately $432,000. Finally, Tibra Equities Europe Ltd bought a new position in ArQule in the 1st quarter worth approximately $530,000. 65.48% of the stock is currently owned by institutional investors.

ArQule Company Profile

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions.

Analyst Recommendations for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players


Leave a Reply

 
© 2006-2018 BBNS.